The expression of Galectin-3 in non-Vδ1Vδ2 cells is also interesting, as recent studies link Galectin-3 production to a poor patient outcome in CRC, increased metastatic potential, and to a γδ17 phenotype, both in healthy tissues and tumours [43, 44]. This evidence concerns the gene LGALS3 and neoplasm.